Not known Details About Ceftriaxone
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage numerous intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis pat